Eli Lilly and Co
Many are betting Ozempic will reduce the need for knee surgery. What it means if they’re wrong
Medical device stocks of all kinds were pummeled over the past week as investors tried to calculate the ripple effects of new weight loss drugs. It wasn’t the first rout in the sector — the pressure has persisted for several months. The fear has been that whenever you have a large group of consumers changing […]
Read More
Monthly Meeting Q&A with Jim Cramer on everything from tech to health care to industrials
During the October Monthly Meeting , we took questions directly from Investing Club members. Here are Jim Cramer’s and portfolio director Jeff Marks’ responses. Their answers have been edited for clarity. 1. Why do rising interest rates have such a negative effect on technology stocks? (Rod) Jim Cramer: When the Federal Reserve started raising rates, […]
Read More
15 stocks with a history of dividend growth are expected to deliver once again this year
Broadcom (AVGO), Caterpillar (CAT) and Eli Lilly (LLY) are among the 15 Club stocks with a streak of annual dividend growth that Wall Street expects to continue in their current fiscal years. Long-term investors should look to own companies with a history of dividend growth instead of chasing stocks with high yields, Morgan Stanley strategists […]
Read More
How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
Danish drugmaker Novo Nordisk has entered a new chapter in its 100-year history — thanks to its newfound success with two products: Ozempic and Wegovy. The drugs are once-weekly injectables of a medication called semaglutide, prescribed for Type 2 diabetes and weight loss. Their skyrocketing popularity has boosted Novo Nordisk to new heights. Novo Nordisk’s […]
Read More
Cramer says Vertex has a drug that may address the ‘largest market opportunity in the world’
CNBC’s Jim Cramer on Monday suggested that investors keep an eye on Vertex Pharmaceuticals (VRTX), a biotechnology company developing a drug to treat acute pain that is not an opioid. “The biggest pharmacy issue [is] how do we get pain removed, or at least nullified, without opiates? They have a plan — Vertex,” Cramer said […]
Read More
Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data
Aykut Karahan | Istock | Getty Images Shares of Structure Therapeutics rose more than 30% on Friday after the biotech startup’s experimental obesity pill succeeded in a small early-stage trial. The once-daily drug helped overweight or obese participants reduce up to 10 pounds of weight on average after four weeks of treatment, according to a […]
Read More
Will weight loss drugs lead to less food consumption? Here’s what Walmart is saying
More than 40% of adults in the U.S. are obese. That’s a big number, which makes the group a force to be reckoned with if their habits start to change suddenly. That’s why we’ve seen so many Wall Street analysts exploring the potential fallout from new weight loss medications like Novo Nordisk’s Wegovy and Ozempic […]
Read More
Ozempic, Wegovy drug prescriptions hit 9 million, surge 300% in under three years
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. George Frey | Reuters U.S. health care providers wrote more than nine million prescriptions for Ozempic, Wegovy and similar diabetes and obesity drugs during […]
Read More